The interplay between ZEB and bHLH proteins at different genes may provide a mechanism for imposing temporal The Zfh family of zinc finger/homeodomain proteins order on the expression of muscle genes.
was first identified in Drosophila where it is required
Zfh-1 is expressed in the CNS, and its overexpression for differentiation of tissues such as the central nervous results in an early embryonic lethal phenotype with severe system and muscle. ZEB, a vertebrate homolog of CNS defects in Drosophila (Fortini et al., 1991) . ZEB is Zfh-1, binds a subset of E boxes and blocks myogenesis also expressed in the CNS, suggesting that it may have a through transcriptional repression of muscle genes. We role in differentiation of other tissues in addition to muscle. present evidence here that ZEB also has an important
In fact, ZEB was described originally in B cells, although role in controlling hematopoietic gene transcription.
no transcriptional activity was reported (Genetta et al. , Two families of transcription factors that are required 1994) . Therefore, we investigated a role for ZEB in for normal hematopoiesis are c-Myb and Ets. These hematopoietic cells. One target of ZEB in myogenesis is factors act synergistically to activate transcription, and the α4 integrin gene (Postigo and Dean, 1997) . α4 is one this synergy is required for transcription of at least of a number of integrins that associate with a common several important hematopoietic genes. ZEB blocks the β1 subunit Springer, 1994) . α4 activity of c-Myb and Ets individually, but together integrin is expressed early in muscle development where the factors synergize to resist this repression. Such it interacts with its ligand vascular cell adhesion molecule repression imposes a requirement for both c-Myb 1 (VCAM-1) to mediate cell-cell interactions important and Ets for transcriptional activity, providing one for myogenesis Sheppard et al., 1994) . explanation for why synergy between these factors is Interestigly, α4 integrin is also expressed in hematopoietic important. The balance between repression by ZEB cells, where it has a key role in the differentiation of and transcriptional activation by c-Myb/Ets provides all hematopoietic lineages through its interaction with a flexible regulatory mechanism for controlling gene fibronectin and VCAM-1 in the stromal matrix and stromal expression in hematopoietic cells. We demonstrate that cells in the bone marrow and fetal liver (Miyake et al., one 
target of this positive/negative regulation in vivo

Introduction
where it continues to function by targeting these leukocytes to sites of inflammation . These The Zfh family is comprised of zinc finger/homeodomain observations, together with recent reports showing that proteins that were first identified in Drosophila where α4 is required in vivo for normal hematopoiesis in mice they are required for proper differentiation of tissues such (Hamamura et al., 1996; Arroyo et al., 1996) , indicate an as the central nervous system (CNS) and muscle (Fortini important role for α4 in hematopoiesis and leukocyte et al., 1991; Lai et al., 1993) . However, the mechanism function. α4 integrin expression continues to be regulated of action of the Zfh protein in Drosophila is unknown. A in mature leukocytes as α4 expression is up-regulated vertebrate homolog of Drosophila Zfh-2, ATBF-1, has during mitogenic activation (Sanchez-Madrid et al., 1986 ) been identified and shown to repress the expression of the and differentially regulated among lymphoid subsets α-fetoprotein gene (Yasuda et al., 1994) . We have found (Shimizu et al., 1990; Picker et al., 1991) . recently that the vertebrate homolog of Drosophila Zfh-1, We demonstrate that ZEB activity, and hence α4 integrin ZEB, represses muscle genes and regulates myogenic expression, is regulated in hematopoietic cells through a differentiation (Postigo and Dean, 1997) . Thus, the Zfh mechanism distinct from that which we have characterized family appears to regulate tissue differentiation by in muscle (Postigo and Dean, 1997) . Instead of being repressing gene transcription.
ZEB binds to a subset of E boxes (CANNTG) with the displaced from the promoter by bHLH proteins, the hematopoietic transcription factor c-Myb synergizes with 76 bp of the α4 promoter gene are active in most cell types , making it unlikely that these Ets proteins to resist repression by ZEB in hematopoietic cells. In addition to regulating the α4 gene, c-Myb and sites alone could account for the restricted pattern of α4 expression. In order to understand how the α4 gene is Ets also play a crucial role in the regulation of other hematopoietic genes and thus in hematopoiesis itself (Graf, regulated in hematopoietic cells, we transfected α4 gene promoter constructs into α4 (ϩ) and α4 (-) cells. 1992; Lipsick, 1996) . Disruption of ets and c-myb genes has been shown to severely affect the proper development
In α4 (-) cells, the activity of the promoter was blocked in constructs containing sequences upstream of -300 bp of multiple hematopoietic lineages (Mucenski et al., 1991; Scott et al., 1994; Muthusamy et al., 1995; Shivdasani (Figure 1A-D) . This pattern of promoter activity was the same as the pattern we found in α4 (-) myoblasts (Figure and Orkin, 1996) . Interestingly, the E26 virus, which carries the v-myb oncogene as a fusion with v-ets, effici-1D, and Postigo and Dean, 1997). Two ZEB sites (at positions -361 and -399 bp) are responsible for this ently induces erythroleukemia, whereas avian myeloblastosis virus (AMV; which carries v-myb but lacks v-ets) silencer activity in myoblasts (Postigo and Dean, 1997) . When the same constructs were transfected into the α4 does not (Radke et al., 1982; Metz and Graf, 1991a,b) , providing evidence of the potent effect of the synergism (ϩ) T-cell line Jurkat, the erythroleukemia cell line HEL or the B cell line Raji, we found that the activity is between c-Myb and Ets in the regulation of hematopoietic genes and specific steps in hematopoiesis. maintained in promoter constructs extending to -2.0 kb ( Figure 1E and F) as α4 (-) myoblasts differentiate into Only a few hematopoietic genes have been identified as targets of c-Myb, and it is interesting to note that α4 (ϩ) myotubes ( Figure 1H ). The lack of repressor activity suggested that ZEB may not be expressed in several of these genes which have been examined in detail are dependent upon synergism between c-Myb and Ets.
hematopoietic cells. However, we found that Jurkat cells express high levels of ZEB (Figure 2A ), and ZEB has Such genes include the early myeloid markers mim-1 (Ness et al., 1989; Dudek et al., 1992) and CD13 (Shapiro, also been shown to be expressed in B cells (Genetta et al., 1994) . 1995), CD4 (Siu et al., 1992) , p56 lck (McCracken et al., 1994) and the early hematopoietic marker CD34 (Melotti In muscle, ZEB is displaced from E361 and E399 by bHLH proteins as α4 (-) myoblasts differentiate into α4 and Calabretta, . It has been demonstrated with some of these genes that expression is (ϩ) myotubes ( Figure 1D and H, and Postigo and Dean, 1997). Even though ZEB is expressed in hematopoietic not induced by c-Myb or Ets separately, but is dependent on the combination of both factors (McCracken et al., cells, it was possible that the ratio of ZEB to bHLH proteins (E proteins) is low and ZEB is prevented from 1994), suggesting that, as with the α4 gene, this synergy may overcome a silencer that blocks activity of the factors binding ZEB sites. However, increasing this ratio by overexpression of ZEB in hematopoietic cells did not individually. Indeed, such silencer elements have been reported in some of the above genes (Allen et al., 1992;  result in repressor activity ( Figure 2B ), contrary to myotubes where overexpression of ZEB displaced Sawada et al., 1994; Perrotti et al., 1995; Duncan et al., 1996) . Although the repressor protein has not been characmyoD/E proteins complexes from E boxes and blocked α4 promoter activity ( Figure 2C , and Postigo and Dean, 1997). terized for CD4 and p56 lck , ZEB sites are evident in both genes, suggesting that ZEB may be responsible for the Next, we examined the capacity of ZEB to bind ZEB sites from the α4 promoter. Gel retardation assays with silencer activity.
Here, we demonstrate that ZEB is important in regulat-E361 and E399 gave the same pattern of nuclear protein binding with nuclear extracts from α4 (ϩ) hematopoietic ing gene expression in hematopoietic cells. Regulation of ZEB activity in hematopoietic cells is distinct from that cells and with α4 (-) cells; we found binding of ZEB along with the ubiquitous bHLH protein USF (upstream in muscle, and our results suggest that a fine balance between repression by ZEB and synergistic activation by stimulatory factor) (Sawadogo and Roeder, 1985) ( Figure  3A and B). However, the ZEB sites bind only weakly to c-Myb and Ets regulates gene expression in hematopoietic cells.
USF, and overexpression of USF did not activate or repress transcription through the ZEB sites (results not shown). Therefore, the lack of repression of the α4
Results
promoter observed in hematopoietic cells was not due to the lack of binding of ZEB to its sites in the α4 promoter.
ZEB is expressed and binds ZEB sites in hematopoietic cells, but it does not repress gene expression ZEB sites are silencers in hematopoietic cells
One explanation for the lack of ZEB repressor activity ZEB blocks muscle differentiation by repressing muscle genes. One such gene is α4 integrin (Postigo and Dean, in hematopoietic cells was that a hematopoietic-specific transcription factor may block ZEB function in the context 1997). In addition to its expression in muscle, α4 integrin has a key role in hematopoietic differentiation, leukocyte of the α4 gene promoter. To investigate this possibility, we first examined the activity of ZEB sites out of the trafficking and recruitment of leukocytes to sites of inflammation (Miyake et al., 1991; Yednock et al., 1992;  context of the α4 promoter. ZEB sites efficiently blocked the activity of the Ets sites from the α4 promoter in α4 . The interaction between α4 integrin on hematopoietic cells and VCAM-1 and (ϩ) hematopoietic cells ( Figure 4A ) as well as in α4 (-) cell types ( Figure 4B ). These results are in contrast to α4 fibronectin on stromal cells and stromal matrix in the fetal liver and bone marrow is important for normal (ϩ) myotubes where the loss of ZEB activity (E361 and E399 did not have any repressor effect on Ets activity) hematopoiesis (Miyake et al., 1991; Roldan et al., 1992) . Previous results demonstrated that Ets sites in the first was the result of the displacement of ZEB by myoD/E12 For transfection in C2C12 myotubes, C2C12 myoblast cells were switched to media containing 2% horse serum and maintained for 4 days before harvesting for analysis of CAT activity as described .
during myogenic differentiation ( Figure 4C , and Postigo in the context of the α4 gene promoter. c-Myb is one of the first transcription factors detected during hematopoiesis, and Dean, 1997). Overexpression of the bHLH E proteins where it has been shown to play a key role in the E12 and E47 did not have any effect on repression by differentiation process (reviewed in Graf, 1992). Addition-ZEB in Jurkat cells ( Figure 4A ), further suggesting that ally, c-Myb has been shown to synergize with Ets factors bHLH proteins do not displace ZEB in hematopoietic in the regulation of hematopoietic genes. The early appearcells as they do in muscle cells (Postigo and Dean, 1997) .
ance of α4 during hematopoiesis suggests that α4 expres-
The hematopoietic transcription factor c-Myb is sion is likely to depend upon a transcription factor such necessary but not sufficient to overcome as c-Myb. Indeed, a number of potential c-Myb sites are repression by ZEB evident upstream and downstream of the ZEB sites (from The results described above suggest that a hematopoietic--130 bp to -2.0 kb) in the α4 promoter ( Figure 5A and data not shown). Gel-shift experiments demonstrated that specific transcription factor may overcome ZEB repression c-Myb/Ets overcome ZEB repression Fig. 3 . ZEB binds ZEB sites in both α4 (-) and α4 (ϩ) cells. Gel retardation assays using a probe containing ZEB sites E361 and E399 from the α4 promoter gave a similar pattern of binding with nuclear extracts from α4 (ϩ) Jurkat cells (A) and α4 (-) HT1080 cells (B). Antibodies (0.5 μg) against ZEB, USF, E12, HEB (this figure) and MyoD and c-Myb (not shown) were added in the binding assays. Only ZEB and USF show binding, as demonstrated by supershift of the corresponding bands (indicated as *). 'NS' indicates non-specific complexes. ZEB and USF binding was competed with a 50-fold excess of unlabeled probe, but not with the corresponding mutant probe (not shown). To determine whether c-Myb was sufficient to activate the α4 gene promoter in α4 (-) cells, an expression vector for c-Myb was co-transfected with α4 gene promoter constructs into the α4 (-)/c-myb (-) HT1080 fibrosarcoma cells. c-Myb overcame the repressor activity of ZEB and activated the α4 gene promoter ( Figure 6A) .
Reporter constructs containing different combinations of Ets sites, ZEB sites and c-Myb sites were then transfected into Jurkat cells [as well as α4 (-) HT1080 cells] ( Figure 6A and B). The activity of the ZEB sites in Jurkat cells was blocked by the combination of Ets and c-Myb sites; however, mutation of either the Ets or c-Myb sites restored repressor activity ( Figure 6B ). These results ZEB fused to the DNA-binding domain (DBD) of the yeast protein Gal4 blocked the activity of the Ets sites ( Figure 6C ), demonstrating directly that ZEB blocks Ets some of these sites bind efficiently to recombinant c-Myb (data not shown). In addition, the -130 to -400 region as transactivation. Additionally, ZEB fused to the DBD of the bacterial protein LexA blocked transactivation by well as individual sites in the α4 promoter were tested c-Myb fused to the DBD of Gal4 ( Figure 6C ), indicating genitors present in the fetal liver was abrogated in the c-myb (-/-) mice ( Figure 8B ), but was high in c-myb (ϩ/ that ZEB blocks the transactivation domain of c-Myb. Thefore, ZEB blocks the transactivation activity of Ets ϩ) mice ( Figure 8C ), indicating that in vivo expression of α4 requires c-Myb. As controls, expression of other and c-Myb individually, but the combination of these sites synergistically overcomes the repression. markers seemed to be unaffected in c-myb (-/-) mice (results not shown). Expression of α4 in other tissues These results suggest that expression of c-Myb is an important determining factor in the control α4 expression such as skeletal and smooth muscle and neural crest derivatives was similar in both the (-/-) and (ϩ/ϩ) in hematopoetic cells. In support of this conclusion, forced expression of c-Myb in α4 (-)/c-myb (-) cells led to genotypes (data not shown), indicating a selective role for c-Myb in the expression of α4 in the hematopoietic system. expression of endogenous α4 on the cell surface ( Figure 7) .
As another way of demonstrating an important role for These results demonstrate a key role for c-Myb in the regulation of the α4 gene, and place α4 as one of the first c-Myb in the regulation of α4 gene expression, we used a dominant-negative form of c-Myb (MT) that contains genes demonstrated to be regulated by c-Myb in vivo. the DBD of c-Myb but lacks the transactivation domain (Badiani et al., 1994) . This dominant-negative c-Myb has Discussion been shown previously to block c-Myb function in vivo and in vitro (Badiani et al., 1994; Taylor et al., 1996) .
ZEB is a vertebrate homolog of the Drosophila Zfh-1 protein. Zfh-1 has been shown to be important in differentiCo-transfection of the MT expression vector with the -2.0α4CAT reporter in Jurkat cells repressed the activity ation of tissues such as the CNS and muscle in Drosophila (Fortini et al., 1991; Lai et al., 1993) . We have found of -2.0α4CAT to a level similar to that found in α4 (-) HT1080 cells ( Figure 8A ). These results provide additional previously that ZEB is an active transcriptional repressor that, like Zfh-1, regulates muscle differentiation (Postigo evidence that c-Myb is required for α4 gene promoter activity in hematopoietic cells.
and Dean, 1997) . ZEB is also expressed in other tissues, and we present evidence here that it may also have a regulatory role in hematopoiesis. Both c-Myb and Ets are Loss of α4 expression on hematopoietic progenitors in c-myb (-/-) mice required for normal hematopoiesis (Shivdasani and Orkin, 1996) . These factors can act in synergy to activate tranc-myb (-/-) mice die in utero due to severe anemia, showing a reduced number of hematopoietic precursors scription, and this synergy is essential for activation of important hematopoietic genes (reviewed in Graf, 1992) . in the liver (Mucenski et al., 1991) . We examined the expression of α4 integrin on hematopoietic cells in embry-ZEB blocks the activity of Ets and Myb individually, but repressor activity is overcome by the c-Myb/Ets synergy. onic day 14.5 c-myb (-/-) mice. If c-Myb is indeed important for expression of α4, then α4 should be absent ZEB sites in the promoter of the α4 integrin gene render expression dependent upon the synergy between c-Myb from hematopoietic cells in these mice. We found that expression of α4 integrin in the hematopoietic cell proand Ets and may provide a explanation for why this synergy blocks α4 expression throughout all hematopoietic cell lineages. Conversely, we found that without ZEB, the α4 gene would be expressed constitutively as a result of the Ets sites in the promoter. This mechanism of regulating ZEB activity and α4 expression in hematopoietic cells is different from what we found previously in muscle cells, where ZEB is displaced from ZEB sites by myogenic bHLH factors that appear during myogenic differentiation (Postigo and Dean, 1997). During development, initial hematopoiesis takes place in the yolk sac (or analogs in mammalians) and paraortic compartments (reviewed in Dorshkind, 1994; Orkin, 1995) . Hematopoietic stem cells migrate from those sites to the fetal liver of the embryo where most of the embryonic hematopoiesis occurs. Perinatally, stem cells migrate to the thymus and bone marrow. Recently, chimeric animal experiments have shown that β1 integrins (a larger subclass of integrins including α4β1) are involved in this migration process (Hirscht et al., 1996) . Hematopoiesis in the fetal liver, thymus and bone marrow requires the interaction of adhesion molecules on the stem cells with ligands in stromal cells. One of the interactions that has been shown in vivo and in vitro to be crucial for normal hematopoietic development is the binding of the α4 integrin on the surface of stem cells to its ligands VCAM-1 and fibronectin in the stroma of these organs (Miyake et al., 1991; Roldan et al., 1992 ). α4 appears on the surface of precursor cells very early during hematopoiesis, before most lineage-specific markers (Sanchez et al., 1993) . Antibodies against α4 and VCAM-1 have been shown to block differentiation of cultured precursors (Miyake et al., 1991; Roldan et al., 1992; Teixido et al., 1992) . Likewise, injection of anti-α4 antibodies into pregnant mice blocked erythropoiesis and inhibited other lineages in the embryos (Hamamura et al., 1996) . Additionally, it has been shown in mice chimeric for α4 that this integrin is required for lymphoid differentiation in the bone marrow (Arroyo et al., 1996) .
Disruption of the c-myb gene causes mice to die in utero due to a failure in liver hematopoiesis, resulting in severe anemia (Mucenski et al., 1991) . Interestingly, the precursors cells present in c-myb (-/-) animals are able to differentiate in culture to their corresponding mature phenotypes, indicating that the defect is in the failure of (Frampton et al., 1996; Taylor et al., 1996) .
50-fold excess of unlabeled wild-type and mutant (mut) c-Myb sites
We found that one result of the disruption of the c-myb from the α4 gene (-134) or the TCR δ enhancer [δE3(3Ј), Hernandezgene is the loss of α4 integrin expression. As outlined Munain and Krangel, 1994] . 'NS' indicates non-specific complexes.
above, the failure of hematopoiesis in the c-myb (-/-) mice appears to result from a failure in proliferation and/ or triggering of apoptosis (Mucenski et al., 1991;  Frampton is required. During differentiation and cell activation, the level of c-Myb varies and, when it is expressed, it et al., 1996; Taylor et al., 1996) . Interestingly, α4 integrin can transmit signals that trigger cell proliferation (Nojima synergizes with Ets factors to overcome ZEB repression and activate hematopoietic genes. We presented in vitro et al., 1990; Damle and Aruffo, 1991) , and adhesion of integrins to ligand has been shown to prevent apoptosis and in vivo evidence that in the absence of c-Myb, ZEB Three μg of -76-G4-CAT (containing five copies of the Gal4 DNA-binding site upstream of the -76α4CAT) was co-transfected in HT1080 cells with 2 μg of G-ZEB which encodes a fusion protein of ZEB with the DBD of Gal4. One μg of pL-G (containing six LexA-binding sites and two Gal4 sites upstream of the E1B TATA box) was co-transfected in HT1080 with 0.5 μg of a Gal4-c-Myb expression vector with or without 2 μg of L-ZEB which encodes a fusion protein between the DBD of LexA and ZEB. (Koopman et al., 1994) . Therefore, the loss of α4 integrin in c-myb (-/-) mice may contribute to the failure of the hematopoietic population to expand, a phenotype observed in these animals (Mucenski et al., 1991) .
Early during hematopoiesis, α4 integrin is expressed in all cell lineages: lymphoid and myeloid precursors, erythroblasts and megakaryocytes (Miyake et al., 1991; Rosemblat et al., 1991; Teixido et al., 1992; Avraham et al., 1993; Sadahira et al., 1995; Hamumura et al., 1996) . As these precursors mature, α4 expression becomes ] (solid line). As a control, β1 integrin showed no of α4 integrin expression continues to be critical beyond significant change in expression. Likewise, no change was seen in the hematopoiesis, where it is expressed differentially on the level of expression of the α5 integrin (not shown). The fluorescence different lymphocyte subsets (Shimizu et al., 1990 ; Picker intensity of an isotype-matched negative control antibody overlaid et al., 1991) , and its expression is up-regulated upon with the expression of α4 integrin in T98G cells (not shown).
mitogenic stimulation (Sanchez-Madrid et al., 1986) . Deregulation of α4 expression has been associated with inflammatory diseases and hematologic malignancies hematopoietic genes). We present evidence that regulation of α4 expression can result from variations of c-Myb (Freedman et al., 1992; Moller et al., 1992; Juneja et al., 1993; Kuriyama et al., 1994) . We propose that control of expression: c-Myb levels (in parallel to α4 expression) decline during hematopoiesis as precursors mature (Graf, α4 integrin expression in hematopoietic cells is the result of a fine balance between repression by ZEB and activation 1992) and increases as a result of mitogenic activation (Torrelli et al., 1985; Pauza, 1987) . Erythroblasts and by c-Myb/Ets. ZEB imposes a requirement for both c-Myb and Ets to activate the α4 gene (and perhaps other megakaryocytes lose α4 expression in parallel with the in most cells that we have tested, it is possible that, like those of c-Myb, their activity varies during hematopoietic differentiation and in different hematopoietic lineages, providing an additional level of regulation. Likewise, it is also possible that the level of ZEB in hematopoietic cells changes during hematopoiesis and/or cell activation. Therefore, in addition to c-Myb, regulation of Ets and/or ZEB activities could add further flexibility to the regulation of the α4 gene (and perhaps other hematopoietic genes regulated by c-Myb/Ets). Although the studies presented here have relied on the comparison of promoter activities in hematopoietic cells versus non-hematopoietic cells, they provide strong evidence that c-Myb and Ets factors synergize to overcome repression by ZEB. While these experiments do not provide conclusive evidence that the c-Myb/Ets-ZEB regulatory pathway plays a critical role in hematopoietic cell differentiation and function, taken together with patterns of c-Myb and Ets expression and the experiments in the c-myb (-/-) mice, these experiments suggest that this balance between repression by ZEB and activation by c-Myb/Ets is involved in the regulation of the α4 gene and possibly several other hematopoietic genes. Interestingly, the combination of c-Myb and Ets did not increase transcription significantly above the level with Ets alone. Therefore, the c-Myb/Ets combination does not overcome repression by ZEB simply by increasing transcription but, instead, the c-Myb/Ets synergy activates transcription through a mechanism distinct from that of either factor alone. It will be of interest to determine the molecular basis for the resistance to ZEB repression. However, further information about how c-Myb/Ets components in a fashion distinct from either factor alone (B and C) α4 is expressed on all hematopoietic cells in E14.5 liver of c-myb (ϩ/ϩ) mice (B) but was not evident on hematopoietic cells in and in a manner that is resistant to disruption by ZEB. the E14.5 liver of c-myb (-/-) mice (C). Frozen sections of E14.5 mice were immunostained with anti-α4 antibody as described . Precursors in the fetal liver of c-myb (-/-) embryos Technologies, Gaithersburg, MD) containing 5% fetal calf serum (FCS) 1993; Sadahira et al., 1995; Hamumura et al., 1996) . regulate α4 expression as c-Myb decreases during their myoblasts (ATCC) and C3H10T1/2 fibroblasts (ATCC) were grown in differentiation, although they still express α4 when they DMEM containing 13% FCS. For differentiation of C2C12 myoblasts reach the bloodstream . Expresto myotubes, cells were changed to DMEM-2% horse serum (Life sion is again up-regulated upon cellular activation Technologies) as described and maintained for (Sanchez-Madrid et al., 1986) . 4 days; by this time Ͼ90% of cells had fused into myotubes. The glioblastoma cell line T98G and its c-myb overexpression derivative
Materials and methods
The Ets family comprises an increasing number of SV-myb-T98G were obtained from B.Calabretta (Jefferson University, members (Leiden, 1993; Wasylick et al., 1993; Crepieux Philadelphia, PA) and mantained in the same media et al. , 1994) . The set of Ets factors that bind the α4 as the HT1080 cell line.
promoter seems to vary from one cell type to another and, at least, includes Ets-1 and GABP α and β (Rosen et al., Plasmid construction α4 promoter deletion constructs have been described previously and unpublished results). The expression and activity et al., 1994) . Numbers in the construct name indicate the amount of of Ets proteins are regulated during T lymphocyte differen-5Ј-flanking sequence present. PSV-CAT has been described previously tiation and activation (Pognonec et al., 1988; Bhat et al. , Weintraub et al., 1995) . Fragments of the α4 gene 1989 , 1990 Muthusamy et al., 1995) . Although we have promoter were obtained by PCR with primers containing KpnI (5Ј) and ApaI (3Ј) sites . The products were digested with found that the Ets sites in the α4 gene promoter are active
KpnI-ApaI and cloned into the corresponding sites upstream of the Ets San Diego, CA), TER 119 antigen (TER119, Pharmingen) and CD45 (I-3/2.3, M.Thomas, Washington University, MO) and examined by sites in -76CAT . For E box constructs, annealed oligonucleotides containing the indicated E box(es) along with either 3 fluorescence microscopy. Cell staining was performed as described (Mucenski et al., 1991) or 10 bp of flanking sequence (results were identical with both) and containing KpnI and ApaI sites were cloned into the corresponding sites upstream of the Ets sites in -76CAT. In E361M, the CACCTG core was
